The stock of Puma Biotechnology Inc (NYSE:PBYI) is a huge mover today! About 3.88M shares traded hands or 255.96% up from the average. Puma Biotechnology Inc (NYSE:PBYI) has risen 34.79% since March 16, 2016 and is uptrending. It has outperformed by 29.25% the S&P500.
The move comes after 7 months negative chart setup for the $1.40B company. It was reported on Oct, 19 by Barchart.com. We have $40.09 PT which if reached, will make NYSE:PBYI worth $84.00 million less.
Analysts await Puma Biotechnology Inc (NYSE:PBYI) to report earnings on November, 14. They expect $-2.05 EPS, down 9.63% or $0.18 from last year’s $-1.87 per share. After $-2.05 actual EPS reported by Puma Biotechnology Inc for the previous quarter, Wall Street now forecasts 0.00% EPS growth.
Puma Biotechnology Inc (NYSE:PBYI) Ratings Coverage
Out of 6 analysts covering Puma Biotechnology Inc (NYSE:PBYI), 5 rate it a “Buy”, 0 “Sell”, while 1 “Hold”. This means 83% are positive. Puma Biotechnology Inc has been the topic of 13 analyst reports since August 27, 2015 according to StockzIntelligence Inc. The stock has “Neutral” rating given by Citigroup on Thursday, September 3. The stock of Puma Biotechnology Inc (NYSE:PBYI) has “Outperform” rating given on Thursday, September 22 by Credit Suisse. The firm has “Buy” rating given on Monday, December 14 by Citigroup. The firm earned “Buy” rating on Monday, April 11 by UBS. RBC Capital Markets downgraded it to “Sector Perform” rating and $36 target price in Tuesday, March 29 report. JP Morgan initiated it with “Overweight” rating and $122 target price in Thursday, August 27 report. The firm earned “Outperform” rating on Tuesday, March 29 by Credit Suisse. The firm earned “Overweight” rating on Tuesday, March 29 by JP Morgan. The rating was initiated by Credit Suisse on Thursday, January 21 with “Outperform”. As per Tuesday, March 29, the company rating was maintained by Citigroup.
According to Zacks Investment Research, “Puma Biotechnology, Inc. is a biopharmaceutical company focused on the acquisition, in-licensing, development and commercialization of novel therapeutics for the treatment of cancer. Its products under development include PB272 (oral neratinib) for the treatment of patients with human epidermal growth factor receptor type 2 (HER2) positive metastatic breast cancer and gastric cancer and PB272 (neratinib intravenous) for the treatment of patients with advanced cancer. Puma Biotechnology, Inc. is headquartered in Los Angeles, California.”
Insitutional Activity: The institutional sentiment increased to 1.21 in 2016 Q2. Its up 0.18, from 1.03 in 2016Q1. The ratio increased, as 24 funds sold all Puma Biotechnology Inc shares owned while 24 reduced positions. 18 funds bought stakes while 40 increased positions. They now own 31.26 million shares or 4.53% more from 29.91 million shares in 2016Q1.
Franklin Street Advsr Nc has invested 0.19% of its portfolio in Puma Biotechnology Inc (NYSE:PBYI). Tower Cap Limited Co (Trc) holds 0% or 687 shares in its portfolio. Checchi Advisers Limited last reported 0% of its portfolio in the stock. Nj State Employees Deferred Compensation Plan last reported 0.06% of its portfolio in the stock. Janus Cap Mgmt Lc reported 2.54 million shares or 0.06% of all its holdings. Ladenburg Thalmann Services Inc last reported 0% of its portfolio in the stock. Orbimed Limited Liability holds 0.92% of its portfolio in Puma Biotechnology Inc (NYSE:PBYI) for 2.96 million shares. Huntington Bank last reported 0% of its portfolio in the stock. Blackrock Fund holds 0% or 602,071 shares in its portfolio. Tourbillon Partners Ltd Partnership owns 587,126 shares or 0.35% of their US portfolio. The New York-based Alliancebernstein Lp has invested 0% in Puma Biotechnology Inc (NYSE:PBYI). Clough Prtnrs Lp holds 0.39% of its portfolio in Puma Biotechnology Inc (NYSE:PBYI) for 246,600 shares. Rock Springs Capital Mngmt Limited Partnership holds 0.07% of its portfolio in Puma Biotechnology Inc (NYSE:PBYI) for 33,000 shares. Federated Investors Pa last reported 50,139 shares in the company. Nationwide Fund Advisors accumulated 0% or 16,108 shares.
More notable recent Puma Biotechnology Inc (NYSE:PBYI) news were published by: Fool.com which released: “Why Puma Biotechnology Inc. Sold Lower Today” on October 19, 2016, also Prnewswire.com with their article: “Puma Biotechnology, Inc. Shareholder Alert: Schubert Firm Investigates Company …” published on October 11, 2016, Fool.com published: “Why Puma Biotechnology Inc Roared Higher Today” on September 20, 2016. More interesting news about Puma Biotechnology Inc (NYSE:PBYI) were released by: Businesswire.com and their article: “PUMA INVESTIGATION INITIATED by Former Louisiana Attorney General: Kahn Swick …” published on October 15, 2016 as well as Finance.Yahoo.com‘s news article titled: “Lawsuit for Investors in shares of Puma Biotechnology Inc (NYSE:PBYI) against …” with publication date: October 04, 2016.
PBYI Company Profile
Puma Biotechnology, Inc., incorporated on September 15, 2010, is a biopharmaceutical firm that focuses on the development and commercialization of products for the treatment of cancer. The Firm focuses on in-licensing the global development and commercialization rights to over three drug candidates, including PB272 (neratinib (oral)), which the Company is developing for the treatment of patients with human epidermal growth factor receptor type 2, or HER2, positive breast cancer, and patients with non-small cell lung cancer, breast cancer and other solid tumors that have a HER2 mutation; PB272 (neratinib (intravenous)), which the Company is developing for the treatment of patients with advanced cancer, and PB357.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.